Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvanted RZV or RSVPreF3 Vaccine in Attenuating Coronary Plaque Progression
NCT07712380Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Primary completion
- May 2029
01
Overview
A Phase 2 trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in cardiovascular disease (CVD), sponsored by GSK. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07712380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712380.